Diets Enriched with Conventional or High-Oleic Acid Canola Oils Lower Atherogenic Lipids and Lipoproteins Compared to a Diet with a Western Fatty Acid Profile in Adults with Central Adiposity.
Western diet
apolipoproteins
canola oil
cardiovascular disease risk
dietary fatty acids
dietary intervention
high-oleic acid canola oil
lipids
lipoproteins
metabolic syndrome
Journal
The Journal of nutrition
ISSN: 1541-6100
Titre abrégé: J Nutr
Pays: United States
ID NLM: 0404243
Informations de publication
Date de publication:
01 03 2019
01 03 2019
Historique:
received:
17
08
2018
revised:
06
09
2018
accepted:
21
11
2018
pubmed:
19
2
2019
medline:
7
11
2019
entrez:
19
2
2019
Statut:
ppublish
Résumé
Novel oils high in monounsaturated fatty acids (MUFAs) and low in saturated fatty acids (SFAs) are an alternative to partially hydrogenated oils high in trans-unsaturated fatty acids. There is widespread use of high-MUFA oils across the food industry; however, limited knowledge of their cardiovascular impact exists. We investigated the effects of diets containing canola oil, high-oleic acid canola oil (HOCO), and a control oil blend (diet formulated to emulate a Western fat profile) on lipids, lipoproteins, and apolipoproteins (apos), as secondary outcomes of the trial. In a multi-center, double-blind, randomized, 3-period crossover, controlled feeding trial, men (n = 44) and women (n = 75) with a mean age of 44 y, mean body mass index (BMI; in kg/m2) of 31.7, and an increased waist circumference plus ≥1 metabolic syndrome criteria consumed prepared, weight-maintenance diets containing canola oil [17.5% MUFAs, 9.2% polyunsaturated fatty acids (PUFAs), 6.6% SFAs], HOCO (19.1% MUFAs, 7.0% PUFAs, 6.4% SFAs), or control oil (10.5% MUFAs, 10.0% PUFAs, 12.3% SFAs) for 6 wk with ≥4-wk washouts. Fasting serum lipids were assessed at baseline and 6 wk. Diet effects were examined using a repeated measures mixed model. Compared with the control, canola and HOCO diets resulted in lower endpoint total cholesterol (TC; -4.2% and -3.4%; P < 0.0001), LDL cholesterol (-6.6% and -5.6%; P < 0.0001), apoB (-3.7% and -3.4%; P = 0.002), and non-HDL cholesterol (-4.5% and -4.0%; P = 0.001), with no differences between canola diets. The TC:HDL cholesterol and apoB:apoA1 ratios were lower after the HOCO diet than after the control diet (-3.7% and -3.4%, respectively). There were no diet effects on triglyceride, HDL cholesterol, or apoA1 concentrations. HOCO, with increased MUFAs at the expense of decreased PUFAs, elicited beneficial effects on lipids and lipoproteins comparable to conventional canola oil and consistent with reduced cardiovascular disease risk in adults with central adiposity. This trial was registered at www.clinicaltrials.gov as NCT02029833.
Sections du résumé
BACKGROUND
Novel oils high in monounsaturated fatty acids (MUFAs) and low in saturated fatty acids (SFAs) are an alternative to partially hydrogenated oils high in trans-unsaturated fatty acids. There is widespread use of high-MUFA oils across the food industry; however, limited knowledge of their cardiovascular impact exists.
OBJECTIVES
We investigated the effects of diets containing canola oil, high-oleic acid canola oil (HOCO), and a control oil blend (diet formulated to emulate a Western fat profile) on lipids, lipoproteins, and apolipoproteins (apos), as secondary outcomes of the trial.
METHODS
In a multi-center, double-blind, randomized, 3-period crossover, controlled feeding trial, men (n = 44) and women (n = 75) with a mean age of 44 y, mean body mass index (BMI; in kg/m2) of 31.7, and an increased waist circumference plus ≥1 metabolic syndrome criteria consumed prepared, weight-maintenance diets containing canola oil [17.5% MUFAs, 9.2% polyunsaturated fatty acids (PUFAs), 6.6% SFAs], HOCO (19.1% MUFAs, 7.0% PUFAs, 6.4% SFAs), or control oil (10.5% MUFAs, 10.0% PUFAs, 12.3% SFAs) for 6 wk with ≥4-wk washouts. Fasting serum lipids were assessed at baseline and 6 wk. Diet effects were examined using a repeated measures mixed model.
RESULTS
Compared with the control, canola and HOCO diets resulted in lower endpoint total cholesterol (TC; -4.2% and -3.4%; P < 0.0001), LDL cholesterol (-6.6% and -5.6%; P < 0.0001), apoB (-3.7% and -3.4%; P = 0.002), and non-HDL cholesterol (-4.5% and -4.0%; P = 0.001), with no differences between canola diets. The TC:HDL cholesterol and apoB:apoA1 ratios were lower after the HOCO diet than after the control diet (-3.7% and -3.4%, respectively). There were no diet effects on triglyceride, HDL cholesterol, or apoA1 concentrations.
CONCLUSIONS
HOCO, with increased MUFAs at the expense of decreased PUFAs, elicited beneficial effects on lipids and lipoproteins comparable to conventional canola oil and consistent with reduced cardiovascular disease risk in adults with central adiposity. This trial was registered at www.clinicaltrials.gov as NCT02029833.
Identifiants
pubmed: 30773586
pii: S0022-3166(22)16575-2
doi: 10.1093/jn/nxy307
pmc: PMC6398388
doi:
Substances chimiques
Fatty Acids
0
Lipids
0
Lipoproteins
0
Rapeseed Oil
0
Oleic Acid
2UMI9U37CP
Banques de données
ClinicalTrials.gov
['NCT02029833']
Types de publication
Journal Article
Multicenter Study
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
471-478Subventions
Organisme : NIA NIH HHS
ID : T32 AG033534
Pays : United States
Informations de copyright
© 2019 American Society for Nutrition.
Références
J Am Coll Cardiol. 2014 Jul 1;63(25 Pt B):2960-84
pubmed: 24239922
Am J Clin Nutr. 2018 Sep 1;108(3):594-602
pubmed: 30084912
Circulation. 2009 Oct 20;120(16):1640-5
pubmed: 19805654
J Clin Lipidol. 2015 Nov-Dec;9(6 Suppl):S1-122.e1
pubmed: 26699442
Clin Chem. 1972 Jun;18(6):499-502
pubmed: 4337382
Br J Nutr. 2011 Feb;105(3):417-27
pubmed: 20875216
Lipids Health Dis. 2010 Dec 01;9:137
pubmed: 21122147
Curr Atheroscler Rep. 2018 Jan 30;20(2):8
pubmed: 29383458
Nutr Rev. 2013 Jun;71(6):370-85
pubmed: 23731447
Trials. 2014 Apr 23;15:136
pubmed: 24754911
Adv Nutr. 2015 Nov 13;6(6):674-93
pubmed: 26567193
Nutrients. 2012 Dec 19;4(12):2097-120
pubmed: 23363999
Prog Lipid Res. 2017 Jan;65:1-11
pubmed: 27793658
J Am Coll Cardiol. 2007 Jan 30;49(4):403-14
pubmed: 17258085
N Engl J Med. 2006 Apr 13;354(15):1601-13
pubmed: 16611951
Cardiovasc Diabetol. 2008 Dec 12;7:35
pubmed: 19077281
Obesity (Silver Spring). 2016 Nov;24(11):2261-2268
pubmed: 27804268
JAMA. 2015 May 19;313(19):1973-4
pubmed: 25988468
Circulation. 2017 Jul 18;136(3):e1-e23
pubmed: 28620111
J Am Coll Cardiol. 2014 Jul 1;63(25 Pt B):2889-934
pubmed: 24239923
J Am Diet Assoc. 2006 Jun;106(6):867-80
pubmed: 16720128
Br J Nutr. 2012 Aug;108(4):682-91
pubmed: 22894911
Am J Clin Nutr. 2014 Jul;100(1):88-97
pubmed: 24829493